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Abstract: Surface-enhanced Raman scattering (SERS) has recently gained increasing attention for the
detection of trace quantities of biomolecules due to its excellent molecular specificity, ultrasensitivity,
and quantitative multiplex ability. Specific single or multiple biomarkers in complex biological
environments generate strong and distinct SERS spectral signals when they are in the vicinity
of optically active nanoparticles (NPs). When multivariate chemometrics are applied to decipher
underlying biomarker patterns, SERS provides qualitative and quantitative information on the
inherent biochemical composition and properties that may be indicative of healthy or diseased states.
Moreover, SERS allows for differentiation among many closely-related causative agents of diseases
exhibiting similar symptoms to guide early prescription of appropriate, targeted and individualised
therapeutics. This review provides an overview of recent progress made by the application of SERS
in the diagnosis of cancers, microbial and respiratory infections. It is envisaged that recent technology
development will help realise full benefits of SERS to gain deeper insights into the pathological
pathways for various diseases at the molecular level.
Keywords: surface-enhanced Raman scattering; biomarkers; multivariate analysis; metabolic
fingerprinting; disease diagnosis; cancer; microbes; volatile organic compounds
1. Introduction
In clinical practice disease diagnosis is a critical step towards disease management and acts as
an indispensable guide towards appropriate treatment and personalised therapy [1]. The initial stage
of disease diagnosis, or differential diagnosis, screens possible disease candidates unambiguously
correlated to empirical clinical symptoms. This crucial process involves a systematic and objective
analysis and understanding of infection-driven changes in complex metabolic processes highlighted
by biological markers (biomarkers) [2]. In addition to stratifying normal biological from pathogenic
processes, biomarkers may provide valuable information about severity and stage of disease, drug
targets and pharmacological response to therapy [3]. Thus, there is always a growing demand to
identify, evaluate and validate disease biomarkers for existing and emerging infections. However,
diseases usually have complex pathogenesis and pathophysiology profiles that involve multiple
intertwined networks of cellular and molecular changes. To capture this biological and biochemical
complexity holistically (e.g., in biofluids, tissues, etc.) indicative of healthy or disease states, intensive
high-throughput omics-based analytical procedures are frequently used [4,5]. These aim to identify and
characterise multiple biomarkers comprehensively to enhance patient outcomes, disease prevention
and drug discovery.
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In metabolomics, gas chromatography (GC) screens and separates different metabolites in complex
sample mixtures, and mass spectrometry (MS) detects mass-to-charge (m/z) ratios to resolve and
identify eluted metabolites [6]. Similarly, genomics, transcriptomics and proteomics techniques, such
as antibody-based and liquid chromatography (LC)–MS, are effective modalities for identifying specific
patterns in biomarkers and pathophysiological mechanisms within the genome, transcriptome and
proteome, respectively [7,8]; we note that LC–MS is also extensively used within metabolomics [9].
Indeed, it is obvious that multiparameter approaches are ideal for biomarker discovery, and have
been shown widely to provide systematic and clearer insights to unravel complex metabolic processes
and pathways underlying various diseases. Nonetheless, when individual diagnostic and prognostic
markers (e.g., metabolites, nucleic acids or proteins) are identified, validated and adopted for routine
clinical use, there should be a paradigm shift towards simple, rapid, molecularly specific and sensitive
analytics for more efficient detection of biomarkers [10]. Additionally, technically demanding and
laborious tools like GC–MS and LC–MS are not cost-effective for diagnosing diseases which lack
definitive biomarkers at present, but are frequently detected through disease-specific changes in
known biomolecules. Preeclampsia is one example, a pregnancy disorder which is characterised
by increased levels of a small subset of molecules, viz., proteins, glucose, uric acid, etc., in human
biofluids [11]. Similarly, therapeutic drug monitoring (TDM), which involves routine monitoring
and tracking of dose dynamics and bioclearance of prescribed drugs to improve therapeutic efficacy,
patient compliance and minimise drug toxicity, requires facile, noninvasive and preferably portable
tools with lower running costs per sample analysis [12]. Due to the highlighted need, the 21st century
has seen an upsurge in the development of simple and high-throughput laboratory analyses to meet
urgent diagnostic requirements in pathology and pharmacology.
Surface-enhanced Raman scattering (SERS) has gained overwhelming attention as a powerful
state-of-the-art platform for disease diagnosis at the molecular level due to superior specificity and
quantitative sensitivity [13]. SERS is a nanoscale vibrational spectroscopy which combines Raman
spectroscopy and plasmonic NPs, to amplify the Raman signals and facilitate trace analysis of
clinically useful biomolecules at ambient conditions. Of particular interest now is the emergence
of portable handheld Raman systems and reproducible enhancing substrates which are directing
SERS for point-of-care (PoC) biosensing. This may overcome biosafety concerns associated with
transportation of infectious biological samples to the laboratory especially during an outbreak of
highly contagious diseases. Additionally, the inherent selectivity and ultrasensitivity of SERS would
enable bespoke clinical diagnostics of subclinical infections like pancreatic adenocarcinoma, which are
asymptomatic until the late stage of infection [14].
Since its discovery, SERS has been successfully applied to a wide range of fields including
environmental [15,16], antibiotic resistance [17,18], food [19,20] and pharmaceuticals [21,22]. However,
it is in the last decade that SERS has become an exciting hypothesis-driven tool for in vitro and
in vivo characterisation of diseases in biofluids, cells or biopsy [23,24]. This is driven by the fact that
SERS profiles reveal detailed molecular structure and abundance dynamics which define specific
diseases with minimal sample handling. Recently, SERS involving direct mixing of human biofluids
and bare NPs yielded promising results for detecting global molecular profiles for diseased and healthy
status [25]. Feng et al. segregated blood plasma of patients with nasopharyngeal carcinoma from
healthy controls with classification sensitivity and specificity of 90.7% and 100%, respectively [25].
Similarly, Shao et al. applied a noninvasive Raman system equipped with a 785 nm laser, and, based
on SERS fingerprints measured from direct mixtures of Ag colloid and serum, cohorts of liver disease
and normal subjects were discriminated with the aid of multivariate analysis [26].
Whilst these studies demonstrate the sensitivity of SERS, it should be acknowledged that
untargeted analysis of biomarkers in chemically diverse samples is very challenging; given that
SERS registers signals of all biomolecules such as proteins, carbohydrates and lipids, present in a
clinical specimen [27]. Thus, SERS spectral bands are composites of complex convoluted vibrational
modes which are extremely difficult to interpret and employ for targeted therapeutics. Needless to
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say, untargeted SERS phenotypic signals do not reveal the structural identity of the actual diagnostic
markers in complex backgrounds. We reiterate here that the major analytical strength of SERS in clinical
diagnostics typically lies in chemical/molecular specificity in combination with the ultrasensitivity
of this technique. On this premise, to realise the maximum benefits of SERS, there is a need to target
known biomarkers identified a priori by other techniques, such as LC–MS or GC–MS, polymerase chain
reaction (PCR), etc. As a case in point, Subaihi and coworkers used reversed-phase LC to separate
therapeutic drugs in human urine followed by quantitative detection by SERS [28]. Furthermore,
specific disease markers can be detected by SERS method, which has been extensively reported
by Graham and Faulds and coworkers [23,29]. Here, SERS signals of target analytes are measured
indirectly through SERS-active reporter molecules and recognition elements adsorbed onto NP surface.
Notably, Gracie et al. employed AgNPs labelled with a fluorescent reporter and biotin modification
probes to detect multiple DNA sequences extracted from etiological agents of meningitis in clinical
samples [30], extending on the picomolar quantitative detection of actual meningitis pathogens
reported previously [31]. When utilised in this manner, SERS produces unique, sharp and well resolved
analyte-specific signature peaks of exceptionally narrow bandwidth and fluorescence-free background.
In this context, SERS can provide answers to the ‘yes’ or ‘no’ diagnostic questions pertaining to the
presence or absence of disease, and importantly, quantitative information based on specific single or
multiple biomarkers. Clearly, when used to its fundamental strength, SERS is a very strong candidate
for quick and reliable qualitative and quantitative diagnostics and interpretation of novel clinical
biomarkers to reveal varying degrees and severity of infections.
The main objective of this focus review is to provide an overview of the current and future utility
of SERS as an information-rich and sensitive bioanalytical platform for rapid disease diagnosis based
on specific biomarkers. A brief SERS tutorial is given, followed by the description of multivariate
chemometrics. Lastly, exciting applications focusing on cancers, microbial and respiratory infections
and an outlook on future work focused on clinical translation of SERS is discussed.
2. Surface Enhanced Raman Scattering: A Brief Tutorial
Previously theorised by Smekal in 1923 [32], the Raman effect was discovered and experimentally
demonstrated by Sir C. V. Raman in 1928 using simple optical materials and instrumental setup [33].
Raman spectroscopy is a specific optical readout platform which involves scattering of irradiated
light following interaction with polarisable molecules under interrogation with a monochromatic
laser source. By far the largest proportion of scattered photons has the same energy as incident light
(known as Rayleigh scattering), and so does not carry significant chemical information [34]. However,
a very small fraction of emergent radiation is inelastically scattered (Raman scattering), with photons
of lower frequency than incident radiation (Stokes scattering) being measured in conventional Raman
spectroscopy. Raman spectroscopy instrumentation has greatly evolved mechanically and technically
over time. Nowadays, powerful and stable lasers, sensitive detectors, optical fibres and software
have accelerated the application of Raman spectroscopy in bioanalytical chemistry. Despite this, the
scattering cross-section of the Raman Effect is still extremely inefficient with a photon conversion rate
of less than 1 per 106–108 incident photons. So to obtain Raman spectra of good signal-to-noise ratio,
high power density, long collection time and clinically unrealistic concentrations are usually required.
Such measurement parameters often initiate fluorescence and photodegradation which frequently
mask Raman spectral lines. This limits the utility of Raman spectroscopy for diagnosis of diseases
in biofluids or cells, where biomarkers may be in trace quantities and preserving sample integrity is
desirable [29]. It is indeed exciting that significant attention has now shifted to SERS to overcome the
quantum inefficiency of conventional Raman spectroscopy.
The SERS effect was discovered accidentally by Fleischmann and coworkers in 1974 at the
University of Southampton (UK), when they observed a dramatic increase in Raman signals of a
monolayer of pyridine adsorbed onto electrochemically roughened Ag electrodes [35]. At that time, the
anomalous observation was thought to be a combined effect of the large surface area of roughened Ag
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electrodes and increased local concentration of adsorbed pyridine molecules. This discovery marked
the beginning of an excitingly new era of physical and surface chemistry, attracting much attention
from analytical scientists and engineers. In 1977, Van Duyne and colleagues [36] and Creighton and
coworkers [37] independently concluded that the observed anomaly in Raman signals of pyridine was
rather due to increased cross-section as a result of enhanced electric fields induced by roughened Ag
electrodes. It was at this time when Van Duyne enlightened the scientific community and coined the
term ‘surface-enhanced Raman scattering (SERS)’ as we know it today.
In principle, SERS involves interactions between electromagnetic radiation and molecules
adsorbed onto, or in close proximity to, nanoscale rough metallic particles of smaller diameter than
the wavelength of excitation radiation [38]. Although there is no comprehensive explanation for the
SERS phenomenon to date, and the topic is under active debate [39], the independent research by Van
Duyne and Creighton, combined with selection rules of molecules adsorbed on metal surfaces [40],
proposed two simultaneously operative theories. The electromagnetic (EM) theory, thought to be
the dominant mechanism, is a physical effect which involves optical excitation of electric fields and
charge motions created by collective oscillations of electrons in the conduction band (surface plasmon)
of NPs. This interaction creates localised surface plasmon resonance (LSPR), the so-called ‘hotspots’
around NP surfaces [41]. Therefore, analyte molecules that interact with LSPR and produce intensified
spectral signals with enhancement factor (EF) of 106–108 compared to conventional Raman lines.
According to the EM theory [42], the SERS intensity (I) is directly proportional to the fourth power
of the local electromagnetic field strength (E4). By contrast, E varies inversely to the distance (d)
between analyte and NP surface, that is, E α (1/d)12. Based on these mathematical expressions, EM is
distance-dependent, and small modification in d and E results in exponential changes in I. Ideally, the
optimum SERS is achieved when an optimal number of analytes are within regions of strong LSPR,
within the interstices of aggregated NPs [43].
The second, chemical enhancement (CM) or charge-transfer mechanism relies on resonance
Raman scattering-like effect. It is thought to involve electronic excitation of covalently bound coupled
electron clouds within chemical bonds formed between analytes and the NP surface. CM increases
polarisability of adsorbed molecules and contributes up to 103 orders of magnitude to the overall SERS
EF [43]. Unlike EM, CM is only significant when molecules are chemically bonded to NPs typically at
monolayer coverage. It is also noteworthy that the Raman effect can be tuned further to 1014 orders
of magnitude to reach fluorescence-like cross-section [44]. This is achieved when incident frequency
excites electronic energy states of specific chromophores near or bonded to the NP surface, giving
rise to surface-enhanced resonance Raman scattering (SERRS). With this large EF, ultralow limit of
detection (LOD) to the extent of single molecule detection were reported by Kneipp and coworkers [45].
Overall, to achieve this optimally huge SERS amplification, several experimental parameters need to
be manipulated including laser wavelength, morphology of NPs and dispersion medium. For more
detailed information on experimental considerations for optimal SERS, readers are directed to excellent
reviews by Stiles et al. and Fisk et al. [42,46]. Quite importantly, optimally aggregated NPs, excitation
frequency overlapped with plasmonic band of NPs and enhancing media with small refractive index
collectively yield large and reproducible EFs [47]. In terms of technical aspect, flow injection and
microfluidics technologies combined with SERS show good SERS reproducibility and reliability [48].
Microfluidics devices consist of microchannels where a minute volume of a sample is mixed uniformly
with NPs at constant and automated flow velocity. Tandem microfluidics-SERS overcomes effects of
localised heating, photodissociation and variations in scattering geometry of NPs. A considerable
focus of recent research has been on developing microfluidic SERS to improve in situ bioanalysis,
which will play a decisive role for clinical utility of SERS in healthcare systems [49].
3. The Affinity of SERS-Active Substrates for Biochemical Molecules
Currently, there is a wide range of solid and dispersed substrates used as SERS enhancement
media ranging from roughened metals to thin metal films to colloidal NPs. Colloids based on coinage
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metals—Ag and Au—are predominantly used in bioanalytical science partly due to ease of preparation
and modification, low-cost, high stability and large EF [50]. Also, Ag and Au nanomaterials exhibit
naturally high affinity for molecules that possess highly electronegative or charged atoms (e.g., oxygen,
nitrogen, sulfur, etc.). Interestingly, numerous biomarkers such as metabolites, nucleic acids and
proteins (the reactants, intermediates and end products of genetically encoded processes), contain
one or more electronegative atoms and polarisable delocalised pi-conjugated system and so they have
strong SERS activity [51,52]. Moreover, since molecular symmetry properties change when molecules
are bonded to the NP surface, centrosymmetric biomolecules are detectable by SERS. Thus, SERS
has unlocked new prospects to apply unique diagnostic information obtained from symmetrical
biomarkers, which would otherwise not be amenable by Raman or Fourier-transform infrared (FT-IR)
spectroscopies, according to the mutual exclusion principle [52].
In general, there are two approaches to accomplish SERS measurements namely, label-free and
label-based techniques as shown in Figure 1. Label-free or intrinsic SERS measures direct interactions
between analytes and NPs [53]. The resultant spectral bands provide detailed intrinsic structural
information and dynamics in biomolecules directly attached to NPs. By contrast, label-based or
extrinsic SERS combines optical activity of plasmonic materials (Ag, Au, Cu, etc.) functionalised
with SERS-active messenger molecules (so-called Raman ‘reporters’), which are resonant with a wide
range of available excitation lasers [30]. The recognition element, e.g., antibody, enzyme, aptamer, etc.,
attached to NP surface binds to epitope(s) of specific target analytes (e.g., a metabolite, nucleic acid or
bacterium) and its plasmonically enhanced characteristic SERS signal is measured indirectly through
the Raman reporter. When several biocompatible recognition elements are employed, extrinsic SERS
offers quantitative multiplexed analysis of biomarkers in complex fluid matrices.
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4. Multivariate Chemometrics
The SERS spectra obtained from biological samples are multivariate in nature. That is to say, they
consist of thousands of complex and combination vibrational modes which are difficult to interpret
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by simple stare & compare. The fundamental tenet of multivariate analysis (MVA) is to simplify
multivariate data systematically to a small number of variables whilst preserving maximum variance
within a data matrix to guide scientific reasoning. This is accomplished through unsupervised and/or
supervised MVA (machine learning) modelling.
Unsupervised MVA explore natural variance within a data matrix using spectral variables in
vertical columns (the X-data) as the only input data measured from objects in horizontal rows
(the Y-data) of a data matrix. Principal components analysis (PCA) is a widely used traditional,
unsupervised approach to reduce data dimensionality, classify spectra into specific groups and to
identify outliers [55]. In principle, PCA decomposes multivariate data into scores (clusters) and
associated spectral loadings. The scores plots consist of uncorrelated orthogonal hyperplanes called
principal components (PCs), which display the differences, similarities and the total explained variance
in the dataset; e.g., cancerous vs. noncancerous conditions. PC1 is extracted from the input X-data
to account for the largest variance, whilst PC2, PC3, . . . PCn (where n is an integer), explain the
remaining natural variance in decreasing order. The PC loadings spectra are plotted to highlight the
most important input spectral variables responsible for the clustering pattern observed on a PCA
scores plot. In the case of disease diagnosis, the variables on a loadings plot often denote intensity
ratio differences and/or spectral band shifts between diseased and healthy groups. Since PCA does
not rely on prior knowledge of investigated samples, it is exploratory by nature which implies that the
algorithm can discover novel hidden biological patterns within samples under review, and is very
useful for outlier detection [56]. Other unsupervised models are dendrograms, self-organising maps,
autoassociative neural network, etc. By contrast, supervised models are calibrated with a known
response variable(s) (the Y-data) to act as building blocks for supervised algorithms.
Discriminant analysis and partial least-squares regression (PLSR) are commonly used supervised
models for classification and quantitative predictions of SERS spectral data [57]. Discriminant function
analysis (DFA) combines PCs extracted from the X-data and a priori knowledge: e.g., sample objects
(classes) in the Y-data to minimise within-class and maximise between-class variance for classification
purposes. On the other hand, PLSR has proved to be powerful and useful in quantitative analysis
of biomarkers by SERS, which employs correlated variables in both X- and Y-data to build a linear
relationship. For PLSR modelling, the sample spectral dataset is first divided into two parts: the
training and test sets. The first subset of sample spectra are used to calibrate or train a PLSR model
followed by quantitative prediction of the remaining unseen samples in the test set [58]. A PLSR model
of good quality or performance will aim to generate a correlation coefficient (R2 or Q2 for trained
and tested sets, respectively), which is close to one and low root mean squared error (RMSE). Partial
least-squares-discriminant analysis (PLS-DA), a variant of PLSR, is also a very powerful multivariate
model particularly applied when the Y-data are categorical by nature [59].
In addition to these linear discriminant analysis methods there are several nonlinear equivalents
that effect nonlinear mapping from input X-data (spectra) to output Y-data (the classes or sample
objects). These are often referred to as machine learning techniques and perhaps the most popular
are support vector machines (SVMs), random forests (RFs) and kernel PLS (kPLS): these are reviewed
in Gromski et al., Mazivila et al., Shinzawa et al., and Ellis et al. [59–62]. The recent resurgence of
interest in artificial intelligence and artificial neural networks (ANNs) has given rise to deep learning.
In these convolution neural networks many different layers are used [63], which are fundamentally
different to the single layer neural networks developed by Rumelhart and colleagues [64]. These
have predominantly been used for image analysis and speech recognition and they are very data
hungry (that is to say require lots of input data) and may have a role in the analysis of chemical images
generated from SERS and Raman microspectroscopy as illustrated by Shi et al. and Krauss et al. [65,66].
As the old saying reveals—“you will reap what you sow”—if a supervised model is incorrectly
calibrated, there is a possibility of overfitting and subsequently false classification or regression.
For accurate prediction, quality control and assurance in disease diagnostics, it is always important
that the number of latent variables is selected carefully and supervised models are validated through
bootstrapping or n-fold cross-validation, etc. [67].
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Examples of where chemometrics has been applied to SERS and related techniques include
detection of cancers using PC-LDA and SVM [68–71], microbial pathogens by various discriminant
and cluster analysis [72–74] and drug and their metabolites by PLS and ANNs [75–77].
5. Applications of SERS in Disease Diagnostics
5.1. Cancer
Cancer is a major public health concern and an economic burden globally. Recent research
indicates that 17.5 million cancer cases were recorded worldwide in 2015, culminating in 8.7 million
deaths [78]. Unfortunately the number of cancer cases increased sharply after two years in 2018 making
cancer the second most common cause of death worldwide [79]. Cancer is a collective term used to
describe malignancies characterised by rapid abnormal growth of cells which invade other parts of the
body. At the onset of cancer, specific biochemical molecules (e.g., proteins) are elevated or decreased
in cancer patients and such dynamics serve as biomarkers for various types of cancers [80]. The early
diagnosis of cancer, especially before metastasis, correlates well with the effectiveness of therapy,
improved patient survival rates and prognosis. To this end, significant effort has been devoted towards
the development of molecular biosensing platforms in recent years to meet the ever-demanding
diagnostics of cancers in human cells, tissues and biofluids. Among these, immunoassays exhibit
considerably high sensitivity and so they are commonly used as noninvasive strategies to measure
biomarkers based on antibody–antigen interactions at different stages of cancer development [81].
The early work to highlight the diagnostic potential of immunoassays used radioisotopes to label
antigens and antibodies to trace dynamics in target markers and metabolism indicative of cancers [82].
Unsurprisingly, the use of radioisotope immunoassay (RIA) in clinics declined due to environmental
health and safety hazards, in addition to costly specialised laboratory facilities and waste disposal
routes for radioactive materials. Enzymes are now commonly used as reporters in the enzyme-linked
immunosorbent assay (ELISA). ELISA is safer, simpler, rapid and the gold standard assay used for
routine analysis of protein cancer biomarkers. Several authors have documented the utility of ELISA
in cancer studies [83,84]. For instance, Ambrosi et al. detected low levels of CA15-3 glycoprotein
antigen mainly observed in patients with breast cancer using anti-CA15-3–horseradish peroxidase
conjugate chemically bonded to an Au solid substrate [85]; whereas Fitzgerald et al. investigated
colorectal cancer by accurately measuring autoimmune responses of IgM and IgG antibodies in human
serum [86]. Nonetheless, long analysis times and high cost of commercial ELISA test kit limit the
application of ELISA. Alternatively, fluorescence-based portable biosensors are well developed and
extensively applied as readout assays. In terms of quantum yield, fluorescence has a large absorption
cross-section, thus fluorescent immunoassay (FIA) has excellent sensitivity which enables detection of
cancer biomarkers at clinically desirable LODs [87,88]. However, FIA has several drawbacks: difficulty
with labelling recognition or target species, limited multiplexing due to frequent spectral overlap
caused by broad emission bands, as well as photobleaching and nonspecific binding, especially at low
analyte levels.
SERS has vital advantages over traditional immunoassays used in clinical biochemistry: it exhibits
multiplexing ability with a single excitation laser and ultrasensitivity leading to absolute quantitative
detection [10] and, if optimized, correctly rivals gold standard assays. Recently, reproducible substrates
based on antibody-conjugated hollow Au nanospheres and magnetic beads were applied for rapid
sensing of carcinoembryonic antigen (CEA)—a biomarker of lung cancer [89]. In this study, the SERS
assay detected low amount (1 pg/mL) of CEA accurately, which was 1000-fold more sensitive than
ELISA. Since the amount of CEA is clinically determined to be about 10 ng/mL in malignant cases [80],
SERS detected subinfectious regime suitable for monitoring and predicting inception of lung cancer
to avoid increased risk of severe metastasis. In subsequent studies, attention shifted towards ex
vivo analysis of human biofluids to test novel biosensors in real biological environments. Within this
framework, Wang et al. analysed diagnostic and prognostic markers of pancreatic cancer, mucin
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(MUC4) protein and serum carbohydrate (CA-19-9) antigen, and compared SERS results to ELISA
and RIA [90]. In addition to quick readout time, SERS demonstrated much better sensitivity (LOD
33 ng/mL) than ELISA (LOD 30 µg/mL) for MUC4, and an LOD of 0.8 U/mL compared to RIA’s
1.0 U/mL for CA-19-9. Interestingly, SERS quantified trace levels of MUC4 in human serum for
pancreatic cancer patients whereas ELISA and RIA failed to register signals under same conditions.
Many other articles have appeared showing that SERS is also versatile as it can detect various cancers
both in vitro and in vivo [91–94].
The last decade has seen substantial progress directed towards the application of SERS for detecting
multiple disease markers simultaneously aimed to reduce risks of false positives associated with singular
biomarker detection and to strengthen differential diagnostics. One of the earliest multiplexed assays
was reported by Faulds, who identified five DNA sequences (5-plex) quantitatively at 1 pM detection
limit within a single assay [95]. Quite recently, a similar sensitivity regime was reported for prostate-free
prostate specific antigens (f-PSA) and complexed prostate specific antigens (c-PSA) [96] and pancreatic
CA19-9, matrix metalloproteinase-7 (MMP7) and MUC4 [97], cancers in 2-plex and 3-plex in human
serum, respectively. The multiplex SERS method shown in Figure 2 of the former study, proposed a
very sensitive and selective sandwich immunocomplex (SIC) nanotags, similar to those reported in
recent years [98,99]. The robust and specific SIC assay showed negligible nonspecific binding and cross
reactivity between f-PSA and c-PSA [96]. This represents a remarkable leap toward reduction of false
positives and assay non-reactivity driven by random binding to interferents which hamper the vast
majority of diagnostic immunoassays. More important, the computed values of free to total PSA ratio
for clinical samples clearly indicated that optimal dual-binding SERS assay can match the sensitivity of
chemiluminescence standard used in clinics.
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Figure 2. (I) Schematic illustration of SERS immunoassay approach for multiplex detection. i. analytical
mixture of free-prostate specific antigens (f-PSA) and complexed prostate specific antigens (c-PSA) with
antibody-conjugated magnetic beads, ii. formation of sandwich immunocomplex (SIC) upon addition
of SERS nanotags, iii. magnetic separation of immunocomplexes and iv. and v. simultaneous detection
of f-PSA and c-PSA in serum, respectively. (II) Quantitative analysis (a) and (b). Characteristics SERS
spectra at different concentrations for f-PSA and c-PSA. (c) Corresponding calibration curves. Reprinted
with permission from Cheng et al. [96]. Copyright © 2017, American Chemical Society.
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Huge efforts have also been made to deploy automated digital microfluidics-SERS for on-site
biosensing of multiple cancer protein markers in minute sample volumes. Recently, a simple
prototype microfluidics-SERS, with minimal sample processing, detected subinfective dose of prostate
cancer [100]. Nguyen et al. and Perozziello et al. quantified breast cancer biomarkers at 6.5 fM in
serum [92] and 0.1 ppm in plasma [101], respectively. The latter study demonstrated a novel sensor for
rapid sorting and quantitative detection of peptides which may play a vital role where multiplexed
analysis tends to be complicated by intermolecular interactions between analyte biomarkers. Other
researchers have gone so far as to suggest multiplex PCR-SERS to study melanoma DNA mutations
associated with various cancers [102]. By combining the biochemical superiority of PCR, and the
sensitivity and specificity of SERS, mutant alleles as low as 0.1% could be identified in serum. This
illustrates the potential of PCR-SERS to guide important clinical decisions regarding tumour biology
with respect to heredity, diagnostics and treatment.
5.2. Microbial Infections–Pathogen Detection
Microbes are found everywhere in large quantities and complex consortia where they perform
specialised functions that play a vital role in ecosystems on which humans depend—quite often within
the superorganism host [103]. However, it is well known that a small proportion of microbes such
as bacteria, fungi and protozoa are responsible for foodborne, waterborne and tuberculosis which
contribute to high mortality and morbidity rates globally [104]. Although local and international
guidelines for combatting diseases are available, microbial infections are still unacceptably high
worldwide with a significant burden borne by the developing world. Just recently perhaps the largest
outbreak of listeriosis, a foodborne infection contracted through consumption of food contaminated
with Listeria monocytogenes bacterium, which occurred in South Africa [105]. The number of affected
confirmed laboratory cases was estimated at 674 with 183 deaths recorded. On the other hand,
waterborne infections are reported to be associated with gastroenteritis cases that claim 2 million deaths
per year globally, and the number of deaths is likely to increase every hour that therapeutic treatment is
delayed [106]. At the time of writing this review, it was reported that at least 54% of chicken meat sold
in Germany supermarkets and 79% of those in slaughter houses were contaminated with Campylobacter
spp. pathogens [107]. Due to the dramatic increase in incidence rates driven by quick transmission,
spread and antimicrobial resistance (AMR) of acute infections, there is an urgent demand for rapid
and ultrasensitive tools to characterise pathogens to protect public health and to prevent potential
bioterrorism. Furthermore, unequivocal identification and differentiation of pathogens, especially at
the PoC, will certainly offer an opportunity to trace the origin of fatal sporadic infections in order to
design effective immediate and long-term corrective action.
Until very recently, routine microbial diagnostics were dominated by traditional platforms based
on culturing, biochemical tests and colony counting [108]. However, these methods are inherently
time-consuming, laborious and centralised (i.e., tests are done in dedicated laboratories rather than on
site), as well as sometimes being inapplicable depending on pathogenic species under investigation.
For example, bacteria such as Mycobacterium tuberculosis may take several days to weeks to form visible
colonies, while selective Campylobacter spp. are biochemically unreactive [109,110]. Alternatively,
immunoassays and molecular tools based on ELISA and PCR have shown much improved rapidity
and applicability [111,112]. These techniques have better detection limits, offer accurate phylogenetic
identity and classification and allow for simultaneous detection of multiple pathogens provided several
antibodies or primers are employed. Although ELISA and PCR have found extensive use in clinical
diagnostics they are costly, labour-intensive, require trained personnel and have long turnaround
times necessitated by pretreatment and enrichment steps. PCR in particular is prone false positive tests
due to cross contamination from the environment and during sample collection, omits phenotypic
characteristics of pathogens and fails to differentiate viable from nonviable infectious pathogens since
the genetic material is always present in live or dead microbial cells. Moreover, the analytical merit of
PCR based on exponential amplification of genetic materials can be a devastating disadvantage in case
of sample contamination [108].
Appl. Sci. 2019, 9, 1163 10 of 24
To bridge the gap, intrinsically robust SERS protocols with little or no sample preparation could be
applied widely for reliable and noninvasive biosensing of microbial infections. The objective of using
SERS is to obtain unique “whole-organism” metabolic fingerprints to discern intrinsic biochemical
content and dynamics of microbial cells. The differential characteristic SERS frequencies of chemical
bonds are used to identify, discriminate and define phenotypes of infectious microbes at species and
strain levels in just a few minutes, as demonstrated previously [18,113]. Of the successful applications
of SERS for microbial diagnostics, the report by Jarvis and Goodacre was the first to study urinary
tract infection (UTI) [72]. In this study, 21 clinical isolates responsible for UTI, including Escherichia coli,
Enterococcus spp., Klebsiella pneumoniae and Proteus mirabilis, were identified and classified accurately
at species and strain level without recourse to DNA methods. To solve reproducibility problems
linked to the simple mixing method applied by Jarvis and other authors [72,114,115], Shanmukh et
al. developed robust clinical grade fabricated solid Ag nanorods to classify molecular signatures
of respiratory syncytial virus (RSV) associated with bronchiolitis [116], whilst Chen et al. proposed
aggregated Au/AgNP covered SiO2 solid substrates to detect phenotypes of resistant etiological agents
of sexually transmitted infections (STIs) in just 10 s [117]. In a further analysis, SERS was extended to
diagnosis of aggressive fungal diseases, in order to discriminate among dermatophyte fungi strains
responsible for mycotic infections using reproducible commercial Ag-coated NPs [118].
Recently, novel SERS employing in situ synthesis of NPs, wherein microbial cells act as
templates for nucleation of NP, has shown much improved reproducibility of the detected microbial
SERS signal. In this method when active microbial cells are soaked in an oxidant (e.g., AgNO3),
metal cations are attracted to anions within cellular biomolecules to act as coordination centres.
A reductant solution (e.g., NaBH4) is then introduced to reduce coordinated metal cations to form
cell wall-bound monodispersed NPs [119,120]. Intracellular deposition of NPs can also be achieved
when oxidants and reductants are added in a reverse order [120]. This approach enhances clinical
applicability of SERS as demonstrated for accurate identification and classification of clinical isolates
of E. coli, Bacillus spp. [120,121], opportunistic Staphylococcus epidermidis [17], Aspergillus fumigatus and
Rhizomucor pusillus [122], and to probe microbial cell functionality [119]. Intriguingly, an in situ SERS
method proved to be very sensitive and effective for susceptibility assessment of clinical pathogens
against common first line antibiotics treatment [17], to complement previous efforts [18,123]. AMR is
considered as one of the biggest public health threats where microbes elude antibiotics designed to kill
them. AMR makes it difficult or impossible to treat some invasive microbial infections. To improve
the management of endemic AMR, Zhou et al. developed a sensitive SERS biosensor to detect
biochemical signatures and status of bacterial infections and AMR rapidly [17]. This SERS biosensor
not only enumerated cells to assess infection severity but also distinguished live (resistant) from
dead (sensitive) E. coli cells challenged with antibiotics based on differential spectral signatures as
illustrated in Figure 3; a result which is practically impossible to achieve by DNA tools like PCR [108].
Whilst lengthy conventional culturing methods can also differentiate live and dead cells for cultivable
organisms, it gives false negative results for viable but non-culturable pathogens.
The practical advantage with SERS here is that unlike in dead cells, metabolically active microbes
can incorporate NPs to their biomolecules in the cell envelope or cytoplasm more effectively that
provide larger and distinctive EF shown in Figure 3. This provides access to vital information about
microbial viability state which is invaluable for tracking the response of causative microbes to
prescribed antimicrobial therapy. Apparently the short time at which AMR was detected in this
study [17] may help to prevent or cure opportunistic infections during surgeries and organ transplants,
and to avoid the use of broad spectrum antibiotics which contribute to increase in AMR. In the
coming years, in situ SERS needs validation through multicentral tests for AMR in a large cohort of
clinical isolates and antibiotics using standardised protocols. Also, the Raman vibrational modes for
heavy water (D2O) are well established [124], and several authors have probed the general metabolic
activity of microbial community members capable of degrading environmental contaminants [124,125].
Similarly, D2O can be incorporated to AMR studies to probe the metabolic activity of sensitive and
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resistant microbes for in-depth assessment and elucidation of bactericidal and bacteriostatic effects
of common and novel antibiotics. Since SERS spectral data provides information on the structural
properties of biomolecules, probing cells with D2O in a time course fashion may identify novel
(multi)-resistant prokaryotes, offer kinetics and mechanistic insights into AMR and treatment prognosis.
In addition, it may reveal valuable biochemical changes in pathogens due to the regulation of drug
metabolism to guide the next generation therapeutics.Appl. Sci. 2019, 9 FOR PEER REVIEW  11 
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The label-free SERS approach can also be complemented by label-based SERS to allow high-level
multiplexed analysis of pathogens in patient samples. Renishaw Diagnostics recently developed
a cutting edge robust SERS-based multiplex tool called Fungiplex assay [126]. This is perhaps the
greatest milestone in recent years which has pushed SERS toward routine clinical use. In its trial
phase, a Fungiplex assay reproducibly detected and identified blood-derived DNA for 12 Candida
and Aspergillus pathogens ex vivo in a single run. Following this, several researchers have launched
ultrasensitive assays of clinical quality for the isolation and quantitative detection of antibiotic resistant
bacteria at 10 cfu/mL [73], DNA of meningitis-associated pathogens at ~21 pM [31], viruses at
10 pg/mL in serum [127] and deadly Ebola virus in blood [128], in 3-plexed analysis, to confirm the
potential of SERS to meet workflow demands for real-time PoC diagnostics. When coupled to rapidly
emerging novel devices—lab-on-a-chip [129,130], microbial- and nano-barcoding [131,132]—SERS has
better stability, ruggedness and analytical performance. This makes SERS undoubtedly exploitable for
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in-field investigations of multiple conflicting coinfections in vivo, especially in remote areas which are
highly susceptible to outbreaks of communicable diseases [128].
5.3. SERS in Breath Analysis
Breathomics is defined as the metabolomics of exhaled air. Human exhaled breath predominantly
consists of water, oxygen, nitrogen, nitric oxide and carbon dioxide. In addition, it contains thousands
of small gaseous volatile organic compounds (VOCs) which are produced by numerous and highly
regulated metabolic reactions in various metabolic pathways [133]. Since the structural identity and
abundance of endogenous VOCs vary depending on the health status of an individual, the field
of breathomics has much potential as a powerful noninvasive platform for biomarker discovery.
Moreover, since each patient produces unique characteristic VOC signatures for specific illnesses,
breathomics will potentially play a crucial role in personalised medicine [134]. Despite attracting
increasing attention, the progress of breathomics research for clinical diagnostics is relatively slow
partly due to limitations associated with capture of breath, and selective and sensitive detection of
trace quantities of VOCs [135].
Electronic nose (eNose) technology is an emerging portable tool for pattern recognition in
composite responses of mixed VOCs (breathprint). Although eNose provides breathprints that can be
used to detect asthma and chronic obstructive pulmonary disease (COPD) [136], it does not identify
individual VOC markers within a complex mixture. Ion mobility spectrometry (IMS) is a relatively
sensitive method though it is destructive, may not be ideal for complex VOC mixtures and its long
term reproducibility is yet to be demonstrated [137]. Currently, GC–MS is the gold standard for global
profiling of exhaled VOCs related to abnormal metabolism and extrapolated to cancers, diabetes etc.
However, if the goal is to develop a rapid analytical tool for online diagnostics and/or offline use
in real-time at the PoC especially in low income countries, then GC–MS is perhaps not convenient.
In addition as partly stated earlier, GC–MS requires professional operators, lengthy procedures, and
high instrument maintenance and consumables costs. This is where SERS prevails in clinical practice
to offer low-cost but quicker detection of disease-specific singular or multiplex VOC targets directly in
exhaled breath at a point of need. The fact that both exogenous and endogenous VOCs are present at
trace concentrations in exhaled breath; SERS is an exciting prospect as it may allow for the detection of
any VOCs adsorbed onto nanomaterials, down to single-molecule level [138].
Although SERS as a clinical diagnostic tool for breath analysis is currently at the budding stage, the
results obtained so far shows unprecedented potential. Initial proof-of-concept work aimed to detect
low amounts of pure acetone and ethanol vapour at LODs of 3.7 pg and 1.7 pg, respectively, as singular
or duplex markers of glucose level in plasma [139,140]. Nevertheless, due to complex pathogenesis
associated with breath-related infections, where multiple biochemical and cellular processes are linked
to innate and adaptive mechanisms, human exhaled breath is chemically complex. Hence, VOC
components should be ‘sorted out’ to improve pathophysiological assessment of various diseases.
An interesting study by Chen et al. was initially applied a high-throughput GC–MS, to capture
this biological complexity, and SERS in parallel, to discriminate between early and advanced gastric
cancer (EGC and AGC respectively) from healthy controls [141]. Using GC–MS and solid phase
microextraction, 14 characteristic volatile metabolites were screened and identified in human exhaled
breath. SERS based on in situ synthesised AuNPs coated on graphene oxide then detected individual
profiles for all 14 VOCs rapidly and accurately in both simulated and real exhaled breath sampled
from patients of gastric cancer. PCA scores plot of SERS successfully discriminated healthy, EGC and
AGC in 200 breath samples at diagnostic sensitivity of >92% and specificity of >83%, very comparable
to that of GC–MS, though quantitative characterisation was not demonstrated [141]. It is worth noting
that SERS profiles were unaffected by age and gender of patients, illustrating the ability of SERS to
overcome effects of between-patient confounding factors in routine clinical tests.
A key prerequisite for successful SERS application in breath analysis is the design of optically
sensitive probes that ‘arrest’ and provide a large surface area for adsorption of volatile metabolites
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since VOCs diffuse quickly according to the Graham’s law [142]. Several SERS substrates with
improved capture properties have been proposed including bimetallic nanogaps [139,143], dendritic
nanocrystals [144] and 3D multilayered nanowires [143]. However, a SERS biosensor designed by
Qiao et al. (Figure 4), where aggregated spherical Au superparticles (GSP) coated with ZIF-8 (so-called
GSP@ZIF-8) formed a 3D core-shell to act as a SERS-active substrate and metal organic framework
(MOF) that is quite attractive [145]. The notable merit of the GSP@ZIF-8 3D structure sensor is the
ability to slow down the flow rate to promote adsorption, retention and equilibration of VOCs, resulting
in increased enrichment and reproducibility. Clearly, GSP@ZIF-8 biosensor is more appealing and
feasible for clinical analysis of specific lung cancer VOC biomarkers in real-time at the point of need.
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by specific invasive pathogens. Bacterial VOCs within exhaled bre th or culture headspac
are istinct, and the r selective recognition s rv s as biomarkers for chronic illne ses [146]. The chemical
structures and identities of a large number of microbial VOCs (mVOCs) bio arkers produced by human
pathogens are available in mVOC database [147]. Hydrogen cya ide emitte by Pseudomonas aeruginosa
associated wi h cystic fibrosis [148], isovaleric cid for Staphylococcus aureus and ethyl acetate and indole
linked to sep is [149], hav all been d tected and quantified accurately by SERS [150], to supplement
recently published results using MS [151,152]. Finally, SERS has been developed to probe the headspace
of bacterial cultures to differentiate accurately viable cells from dead bacteria after treatment with the
antibiotic gentamicin [153]. Henceforth, such VOC biomarkers will be identifiable in new patients with
the same infections. It is very clear here that SERS offers dual benefits for healthcare: the rapid and
sensitive detection of actual microbial pathogens and their phenotypic characteristics down to a single
cell and the corresponding VOC molecular signatures as confirmatory results simultaneously.
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6. Conclusions and Future Outlook
In this review, we have discussed recent applications of SERS and shown that this method is a
versatile physicochemical tool that can be used to extract diagnostic and quantitative information
within cancers and microbial infections, as well as in respiratory disease. Both direct and indirect
SERS play vital roles in targeted detection of specific biomarker in cells or human biofluids and their
use have been extended to several diseases in need of urgent attention. However, to harness full
analytical capabilities and to accelerate translation of SERS to the clinic, there are pending technical and
methodological issues that need urgent improvements. We know very well that SERS peak intensity
or area is linearly proportional to the concentration of sample analytes which facilitates accurate
quantitative detection of diseases. However, due to saturation of NP surfaces in label-free SERS,
whereby some molecules reside outside the LSPR, or instability of a radiation source and inconsistent
cumulative aggregation, reproducibility and linearity are lost. To overcome this problem in quantitative
analysis, a suitable internal standard (IS) can be integrated so that characteristic biomarker bands are
normalised to distinct IS peak. This reduces spectral signal fluctuations since analyte and internal
standard spectral bands are affected in exactly the same way, especially when isotopologues are
used as illustrated recently [154,155]. Alternatively the standard addition method can be used as this
also accounts for any sample background as shown for the quantification of uric acid in the urine
of pregnant individuals [156]. This way quantitative detection and prediction of disease/prognostic
markers in a clinical environment would be more accurate and reliable. One other area which perhaps
needs more attention to simplify SERS interpretation is the use of functionalised NPs (label-based
SERS) for selective detection of specific markers within complex backgrounds. It is worth noting that
reporters and capture species prevent undesirable aggregation of NPs and resolve known multiple
biomarkers simultaneously without any prior separation or enrichment procedures.
The use of SERS in parallel with multiparameter tools is also showing promising trends; it is clear
that SERS has improved time between diagnostics and cure, specificity and quantitative analysis of
biomarkers identified by chromatography and spectrometry. Moreover, several problematic issues,
due to nonspecific binding or cross-reactivity among untargeted species, NPs and capture elements,
especially polyclonal antibodies, which hampered detection of desirable targets, have been addressed in
recent years. Generally, a series of washing steps and biocompatible coating materials such as polymers
and silica as protective layers or core/encapsulation-shells have been applied successfully. The main
objective here is to prevent leaching of Raman reporter and capture probes, enhance specificity and to
shield interfering contaminants from accessing NP surfaces and paratopes of capture elements.
Another fundamental area of focus for reliable interpretation of biomedical SERS in future
is spectral band assignment. For bacterial SERS, metabolomics and isotopic labelling experiments
have played an indispensable role; we now understand significant contributions of purines and
pyrimidines to characteristic SERS spectral bands [157,158]. Nonetheless, there is still a pressing need
to formulate standard operating protocols and a unified library of reference biomaterials for SERS
to allow for repeatability, unambiguous and detailed understanding of molecular dynamics and
metabolic pathways. In light of this, it should be emphasised that only when pending problems
are effectively overcome will SERS be convincingly relevant and acceptable to clinicians. For now
the SERS community should aim to provide experimental details including sample preparation, NP
synthesis/properties (e.g., plasmonics and morphology), how NPs and analytes are brought into
contact, excitation wavelength used, signal acquisition parameters and data processing employed, as
part of the minimum reporting standards.
Lastly, theranostics is an emerging interesting area of clinical diagnostics where SERS will play
a crucial role as revealed by recent reports [159]. Theranostics combines diagnosis of disease and
therapeutic treatment simultaneously. Ag- and Au-NPs have high optical activity and large surface
area for functionalisation, and so they are attractive for diagnosis of specific diseases, photothermal
therapy and TDM. This means that NPs can provide large optical enhancement and rapid quantitative
assessment of disease at trace amounts whilst delivering therapeutic drugs to intended targets. Due to
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good biocompatibility, AuNPs can migrate across cellular membranes into the cytoplasm to give a
snapshot of intracellular chemical processes and metabolic flux distribution without causing significant
damage. When coupled to automated microfluidics or LoC devices and deep machine learning, SERS
would permit in/off/online platform to monitor therapeutic drug activity and patients’ response
to new drugs in real-time. However, disease diagnosis by SERS should be validated carefully and
comprehensively, which may include confirmatory inputs from techniques presented in Table 1. This
is aimed to avoid costly and risky unpredictable analytics like the blood testing system which led
to the ‘Theranos scandal’, perhaps the biggest science saga of the 21st century to date. It is clearly
evident that theranostics-SERS interface along with MVA will potentially revolutionise patient care,
AMR biochemistry and drug discovery by expanding on the diagnostics and therapeutics toolbox for
clinicians in the foreseeable future. We are hopeful this review will contribute to the ongoing efforts to
translate vibrational spectroscopy to the clinic, spearheaded by the international society for clinical
spectroscopy (CLIRSPEC) [160].
Table 1. A summary of different types of enhanced Raman scattering techniques commonly used in
disease diagnostics.
Enhanced Raman Techniques Brief Description
Resonance Raman
(RR) scattering
RR occurs when the incident frequency excites electronic energy (EE) states of specific
molecules; e.g., aromatic chromophores, and this aids the detection of pathogens [161].
If the EE level is excited by laser frequency in the ultraviolet (UV) region, the technique
is UVRR, and can be susceptible to photodissociation [162].
Spatially offset Raman
spectroscopy (SORS)
SORS collects distinctive chemical information and images from deep subsurfaces
(including analytes in opaque containers) of a sample. SORS spectral signals are
recorded when backscattered Raman photons are collected at points spatially offset
(∆x) from the point of illumination (x). Negligible photodissociation, allowing for
noninvasive deep medical diagnostics [163].
Surface-enhanced spatially offset
Raman spectroscopy (SESORS)
SORS combined with NPs that enable SERS: that is to say subsurface information is
measured from molecules in the vicinity of or chemically bonded to SERS substrates.
Negligible fluorescence and excellent background contrast, specificity and sensitivity




A variant of SESORS where incident frequency matches the EE of molecules near
SERS-active substrates. SESORRS increases spectral signals further by orders of
magnitude to provide extra biochemical selectivity and sensitivity, theoretically better
than SESORS, as demonstrated by Fay et al. for breast cancer detection [166].
Tip-enhanced Raman
spectroscopy (TERS)
Similar to the SERS phenomenon, but here a single SERS-active AFM probe whose
sharp pointed apex (tip) is covered in NPs and scans through biomolecules on a
sample surface, resulting in highly confined plasmonic enhancement (electrostatic
lightning rod and SPR effects). Improves lateral spatial resolution to as low as 10 nm,
about the diameter of the tip probe. Achieves single molecule detection and
discrimination of bacterial pathogens [167,168].
Stimulated Raman scattering
(SRS)
Two lasers provide a pump (ωp) (similar to conventional Raman) and Stokes (ωs) beam
frequencies that intersect at the sample surface. The energy difference (∆ω = ωp − ωs)
between the beams matches the frequency (Ωvib) of molecular bond vibrations, leading
to larger scattering cross-section as a consequence of stimulated Raman excitation. No
nonresonance background [169], making SRS ideal for in vivo medical imaging to
improve disease diagnostics [170].
Coherent anti-Stokes Raman
scattering (CARS)
Like SRS, CARS employs two lasers of frequenciesωp andωs. When molecular bonds
whose Ωvib coincide with ∆ω (as in SRS), anti-Stokes (as) lines are produced at
frequency ωas = 2ωp − ωs. Thus, analytes are excited twice, from the ground to first
and second excited states before relaxing back to the ground state. Though prone to
nonresonance background effects which may limit the quantification of target
analytes [171], CARS is effectively applied for disease detection including differential
diagnostics of cancers [172].
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